EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine

Fabian Watermeyer, Arnim Johannes Gaebler iD, Irene Neuner, Ekkehard Haen, Christoph Hiemke, Georgios Schoretsanitis, Michael Paulzen iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Fabian Watermeyer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Quetiapine Fumarate, Drug Interactions, Dipyrone, Polypharmacy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Metamizole is quite an old drug with analgesic, antipyretic and spasmolytic properties. Recent findings have shown that it may induce several cytochrome P450 (CYP) enzymes, especially CYP3A4 and CYP2B6. The clinical relevance of these properties is uncertain. We aimed to unravel potential pharmacokinetic interactions between metamizole and the CYP3A4 substrate quetiapine.

Methods

Plasma concentrations of quetiapine from a large therapeutic drug monitoring database were analysed. Two groups of 33 patients, either receiving quetiapine as a monotherapy (without CYP modulating comedications) or with concomitantly applied metamizole, were compared addressing a potential impact of metamizole on the metabolism of quetiapine being reflected in differences of plasma concentrations of quetiapine and dose‐adjusted plasma concentrations.

Results

Patients comedicated with metamizole showed >50% lower plasma concentrations of quetiapine (median 45.2 ng/mL, Q 1 = 15.5; Q 3 = 90.5 vs . 92.0 ng/mL, Q 1 = 52.3; Q 3 = 203.8, P = .003). The dose‐adjusted plasma concentrations were 69% lower in the comedication group ( P = .001). Subgroup analyses did not suggest a dose dependency of the metamizole effect or an influence of quetiapine formulation (immediate vs . extended release). Finally, the comedication group exhibited a significantly higher proportion of patients whose quetiapine concentrations were below the therapeutic reference range (78.8% in the metamizole group vs . 54.4% in the control group, P = .037) indicating therapeutically insufficient drug concentrations.

Conclusion

The combination of metamizole and quetiapine leads to significantly lower drug concentrations of quetiapine, probably via an induction of CYP3A4. Clinicians must consider the risk of adverse drug reactions, especially treatment failure under quetiapine when adding metamizole.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quetiapine FumarateDrug InteractionsDipyronePolypharmacyCytochrome P-450 CYP3AAntipsychotic AgentsHumansFemaleMaleMiddle AgedAgedAdultDrug MonitoringAnti-Inflammatory Agents, Non-SteroidalAged, 80 and overDose-Response Relationship, Drug

Stichwörter der Autor:innen

cytochromeinteractionmetamizolepharmacokineticsquetiapinetherapeutic drug monitoring

Substanzen

Quetiapine FumarateDipyroneCytochrome P-450 CYP3AAntipsychotic AgentsCYP3A4 protein, humanAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen, Aachen, Germany.
  • JARA-Translational Brain Medicine, RWTH Aachen University, Aachen, Germany.
  • Institute of Physiology, University Hospital RWTH Aachen, Aachen, Germany.
  • Department of Psychiatry and Psychotherapy, Clinical Pharmacology, University of Regensburg, Regensburg, Germany.
  • Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany.
  • Clinical Pharmacology Institute AGATE gGmbH, Pentling, Germany.

ORCID-Profile: Arnim Johannes Gaebler, Michael Paulzen

Zitieren

APA

Watermeyer, F., Gaebler, A. J., Neuner, I., Haen, E., Hiemke, C., Schoretsanitis, G., & Paulzen, M. (2024). Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16168

Vancouver

Watermeyer F, Gaebler AJ, Neuner I, Haen E, Hiemke C, Schoretsanitis G, et al. Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16168

BibTeX
@article{Watermeyer2024,
  author = {Watermeyer, Fabian and Gaebler, Arnim Johannes and Neuner, Irene and Haen, Ekkehard and Hiemke, Christoph and Schoretsanitis, Georgios and Paulzen, Michael},
  title = {Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16168}
}
Kostenlos starten →